Kornimate/medical-research-clean huggingface dataset:
the effect of enhanced recovery after surgery in endoscopic sinus surgery

Conditions: Chronic Rhinosinusitis (Diagnosis); Surgery

Summary: enhanced recovery after surgery (eras) protocols have been widely applied during perioperative periods for different diseases, there are few reports of eras in patients undergoing endoscopic sinus surgery (ess). this study therefore aimed to evaluate the benefits of eras protocol compared to traditional care following ess.


Eligibility criteria:
inclusion criteria: * the patient has crswnp need endoscopic sinus surgery for treatment. exclusion criteria: * age under 18 years * pregnant * asa grade iv * received oral or topical steroids within 4 weeks preceding surgery * had previous ess history * intolerant to nsaids * comorbidity of severe mental disease * not compliant with therapy.
not invasive monitoring of pleural drainage

Conditions: Pleural Effusion

Summary: this study investigates if data about monitoring the drainage of pleural effusion can be collected by non invasive sensors (feasibility).

25 patients \> 18 years old with pleura effusion will be examined with regard to the feasibility of non invasive sensor measurements corresponding to the course of thorax impedance and respiration parameters during body fluids loss before and after pleural drainage. the measured data will be compared to standard routine reference measurements (heart rate, medication, brain natriuretic peptide (bnp), heart minute volume). additionally heart sound analysis via electronic stethoscope will be compared to standard methods. also 25 healthy controls will undergo the same measurements to receive standard values.

Eligibility criteria:
inclusion criteria: * patients with pleural effusion undergoing pleural drainage * male and female patients aged at least 18 years exclusion criteria: * pregnancy or breast feeding * implanted pacemaker / cardiac resynchronization therapy (crt) / implanted cardioverter defibrillator (icd) except medtronic device "optivol". * patients not being able to consent

Keywords: pleural effusion pleural drainage thorax impedance respiration parameters heart sounds analysis
pne plus exercise versus exercise for chronic rotator cuff tendinopathy

Conditions: Rotator Cuff Tendinosis

Summary: the aim of this randomized controlled trial is to evaluate the combined effects of pain neuroscience education plus exercise to exercise alone in the management of patients with chronic rotator cuff tendinopathy regarding pain, function, strength, kinesiophobia, and pain catastrophizing.


Eligibility criteria:
inclusion criteria: * shoulder pain due to rotator cuff tendinopathy lasting more than 6 months. * internal rotation resisted strength test positive. * test item cluster (hawkins-kennedy, painful arc, and infraspinatus test) positive. exclusion criteria: * history of: tumors, metastasis, osteoporosis, shoulder fractures, shoulder luxation and/or instability, previous shoulder surgery, cervical radiculopathy, full-thickness rotator cuff tears, glenohumeral joint degeneration, inflammatory arthropathy, acromioclavicular joint arthrosis, and rotator cuff calcifications. * being treated by other physical therapy or medical treatment for their shoulder pain at the time of recruitment.
perceived barriers of cervical cancer screening in reunion island and key levers for improvment

Conditions: Uterine Cervical Neoplasms

Summary: fosfore study aims at identifying the barriers of cervical cancer screening in reunion island and key levers for improvment.

fosfore is a cross sectional kabp (knowledge, attitudes, beliefs and practices) telephone survey on cervical cancer screening from a sounding board of women aged between 25 and 65 years and living in reunion island. sample size was estimated from local datas on cervical cancer screening.

Eligibility criteria:
inclusion criteria: * women aged between 25 and 65 yo * living in reunion island * speaking french, creole or shimaore language * able to answer phone exclusion criteria: * history of hysterectomy * history of incomplete or total conisation

Keywords: cervical cancer screening barriers
maternal and infant cord blood monosaccharide content

Conditions: Pregnancy

Summary: mother's breast milk provides many benefits to babies with regard to development and improved health. we believe the simple sugars which make up these complex sugars in breast milk and are also found in the brain may be critical to normal brain development in term and preterm infants. babies are exposed to these sugars by placental transport during pregnancy and through mother's breast milk after they are born. for the preterm infant, we do not know if breast milk gives enough of these sugars compared to what the baby gets during pregnancy. a maternal blood sample and blood samples from the baby's umbilical cord will provide us with background information for developing a supplement of special sugars that can be added to infant formulas to provide the amount that the baby usually gets during pregnancy and from breast milk.


Eligibility criteria:
inclusion criteria: * healthy mothers with ages ranging from 18 to 35 yrs * delivered infants appropriate weight for gestational age (between 10% and 90%) exclusion criteria: * maternal history of smoking, alcohol or drug use

Keywords: breastfeeding infant preterm nutrition
bio|concept.ecg-library (collection of ecg signals for development of algorithms)

Conditions: Heart Diseases; Rhythm; Abnormal

Summary: collection of holter surface ecgs for the development of new sensing and detection algorithms

the aim of the study is to collect data from surface ecgs by using holter ecg recordings from patients with different forms of diagnosed arrhythmias and/or specific ecg characteristics from heart diseases to support the development of new sensing and detection algorithms for implants.

Eligibility criteria:
inclusion criteria: * patient is able to understand the nature of the study and willing to provide written informed consent. * patient is willing and able to attend holter ecg procedure following a visit * history of at least one of the following conditions (established via ecg prior to enrollment): (a) patient with pacemaker/icd and 1. ventricular stimulation \> 30 % or (b) patient either without pacemaker/icd or with pacemaker/icd, but without significant atrial and ventricular stimulation and at least one of the following: 2. frequent ventricular extrasystoles (ves) (incl. bigeminus) or 3. atrioventricular reentrant tachycardia (avrt)/wolff-parkinson-white (wpw) syndrome or 4. atrioventricular nodal reentrant tachycardia (avnrt) or 5. sinus tachycardia at rest or 6. atrial flutter or 7. any form of ventricular tachycardia (vt) or 8. silent/paroxysmal/persistent/permanent af or 9. brugada syndrome or 10. long qt syndrome or 11. right bundle branch block (rbbb) or 12. left bundle branch block (lbbb) or 13. myocardial ischemia/acute myocardial infarction or 14. other abnormal qrs(t) complex, st segment or t-wave morphology, i.e. any other qrs anomaly / st segment elevation / st segment depression / t wave changes exclusion criteria: * any condition which precludes the patient's ability to comply with the study requirements. * known allergy to patch electrodes. * pregnant or breast feeding. * less than 18 years old. * participation in another interventional clinical investigation

Keywords: holter ecg recording
a comparative study on efficacy and safety of add-on sulforaphane or rtms to escitalopram for major depressive disorder with poor response to initial treatment

Conditions: Major Depressive Disorder

Summary: a 12-week, randomized controlled trial (rct) with parallel grouping design will be conducted to compare the efficacy and safety of different treatments. one hundred and eighty adults diagnosed with major depressive disorder (mdd) with no or poor response to initial antidepressant treatment will be recruited. then all the patients will be 1:2:2 randomly assigned to different intervention groups including escitalopram, escitalopram plus sulforaphane (sfn) , and escitalopram plus repetitive transcranial magnetic stimulation (rtms). clinical symptoms and side-effects will be evaluated or recorded using the 17-hamilton depression rating scale (17-hdrs), the hamilton anxiety scale (hama), side-effects sheet, etc., at critical decision points (cdp) including weeks 2, 4, 8 and 12 after treatment. blood cell counting, biochemical, and electrocardiogram examination will be performed at weeks 4, 8 and 12 after treatment in order to evaluate the effect of different interventions on the physical condition. in addition, niacin skin flush response and serum markers including nuclear factor erythroid-2-related factor 2(nrf-2), p-nrf2, malondialdehyde (mda), superoxide dismutase (sod) and erythrocyte glutathion peroxidase (gpx) will be tested at baseline and endpoint. the primary outcome is the reduction rate in 17-hdrs total score from baseline to the end of the study. the secondary outcomes include changes in niacin skin flush response test and levels of serum markers. all the data will be analyzed by spss software.


Eligibility criteria:
the inclusion criteria are as follows: 1. aged 18-60 years; 2. diagnosed with moderate or severe depressive disorder according to the criteria of the dsm-5; 3. total score of 17-hdrs≥17; 4. never receiving electroconvulsive therapy (ect)/modified ect (mect)/rtms or other treatments in the past month; 5. no response or poor response (having a reduction of \<20% on the total score of the 17-item hamilton depression scale compared with the baseline) to adequate antidepressants (except escitalopram) treatment for at least 4 weeks; 6. having sufficient audio-visual ability and comprehension; 7. signed informed consent statements. the exclusion criteria are as follows: 1. serious or active somatic illness (abnormal index values were more than twice the limit of normal); 2. a history of mania/hypomania; 3. current high risk of suicide (score of item 3 of 17-hdrs ≥ 3); 4. pregnant or lactating women, or planning pregnant women; 5. taking immunosuppressants or vitamins recently.

Keywords: major depressive disorder; sulforaphane; rtms; efficacy; oxidative stress; marker; add-on
heparin antagonisation in transcatheter aortic valve implantation

Conditions: Aortic Valve Stenosis; Transcatheter Aortic Valve Implantation; Protamine Sulfate Overdose

Summary: unfractioned heparin is usually given in a defined dosage during transfemoral tavi. activated clotting time (act) is usually used to measure the heparin effect. act-analysis is easy to perform at the bedside, but susceptible to interference effects. at the end of the procedure, protamine is given to reverse eventual residual heparin effect. an overdose of protamine can impair the coagulation itself. the investigators want to analyse the effect of a partial heparin reversal by rotem analysis.


Eligibility criteria:
inclusion criteria: * severe aortic valve stenosis * transfemoral tavi as best therapy option * unfractioned heparin for periprocedural anticoagulation exclusion criteria: * known hypersensitivity /allergy to unfractioned heparin or protamine * acute systemic infection * pre procedural started and ongoing intravenous therapy with unfractioned heparin * severe periprocedural adverse event with the need for emergency surgery (with or with our cpb) * refusal of the patient to participate

Keywords: anticoagulation
development of a cinical and biological database in ovarian, fallopian tube and peritoneal cancers

Conditions: Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms

Summary: a clinical and biological database will provide to the scientific community a collection of blood and tissues with clinical datas to improve knowledge about cancer and help to develope new cancer treatments. this database is specific to epithetial ovarian cancer, fallopian tube cancer and primitive peritoneal cancer.

a clinical and biological database is a collection of reliable, prospective and representative datas. this collection, provided to the scientific community, will help to develope research programs such as : * cinicals and biological predictive factors of treatments response * identification of biological tumoral markers associate with survival * identification of prognosic factors after recidivism * diagnostics tests optimisation and follow-up from blood samples ( circulating tumor cells (ctc) ) * developing strong preclinical models. those models would be later used to test alternative treatments and would help to identify new biomarkers

Eligibility criteria:
inclusion criteria: * 18 or older * patient at the diagnosis of an epithelial ovarian cancer, or a fallopian tube caner or a primitive peritoneal cancer * patient eligible for, at least, one surgery and a chemotherapy * patient having given his informed, written and express consent exclusion criteria: * patient not affiliated to a social protection scheme * pregnant and / or nursing women * subject under tutelage, curatorship or safeguard of justice * patient whose regular follow-up is impossible for psychological, familial, social or geographical reasons

Keywords: biological specimen banks cancer gynecology
aspirin, heparin and miscarriage

Conditions: Pregnancy; Miscarriage

Summary: efficacy of low dose aspirin (lda) versus lda plus low-molecular-weight-heparin (lmwh) in patients with a history of recurrent miscarriages.


Eligibility criteria:
inclusion criteria: * pregnant women * history of 2 or more of miscarriage exclusion criteria: * twins

Keywords: aspirin heparin pregnancy miscarriage
disulfiram as a modulator of amyloid precursor protein-processing

Conditions: Alcohol Addiction

Summary: a causal therapeutic approach for treatment of alzheimer's disease has not been established so far. the protein adam10 represents a promising target for an a-beta peptide preventing strategy. treatment of human neuronal cells with disulfiram, a drug which is used in clinical routine for recrudescence prevention of alcohol dependency, revealed an increased expression of adam10. this finding indicates a neuroprotective potential of disulfiram. the investigators' research purpose aims at the verification of the results obtained in cell culture experiments in the human organism. therefore, include alcohol addicted patients were included, which take the drug disulfiram for recrudescence prevention, in our study. patients are recruited from the patient-collective of the university medical center mainz and the central institute for mental health mannheim. blood samples (max. 5 ml) are taken from the participants before the intake of disulfiram and about two weeks after treatment. demographic data are collected (such as age or onset of addiction). gene expression is analyzed via reverse transcription polymerase chain reaction(rt-pcr) from blood cell-derived messenger ribonucleic acid (mrna).


Eligibility criteria:
inclusion criteria: ambulant or stationary patients, which receive disulfiram for recrudescence prevention exclusion criteria: diagnosed alzheimer's dementia previous disulfiram treatment less than four weeks before baseline blood collection

Keywords: app-processing disulfiram adam10 alzheimer's disease blood
an efficacy and safety study of morab-003 in platinum-resistant or refractory relapsed ovarian cancer

Conditions: Ovarian Cancer

Summary: the study is being conducted to find out if paclitaxel works better when given together with an experimental drug called morab-003 (farletuzumab) or alone in patients with platinum-resistant or refractory relapsed ovarian cancer

safety was assessed by the monitoring and recording of all adverse events (aes), including drug hypersensitivity adverse events (dhae), and serious adverse events (saes); clinical laboratory test (serum chemistry, hematology, urinalysis); tolerability (discontinuations, treatment delays, dose reductions); physical examinations (including vital signs assessment); 12-lead electrocardiograms (ecg) obtained in triplicate and reviewed by independent blinded cardiologist, and karnofsky's performance status.

Eligibility criteria:
inclusion criteria: * diagnosis of non-mucinous epithelial ovarian cancer, including primary peritoneal and fallopian tube malignancies, measurable by ct or mri scan assessed within 4 weeks prior to study entry * must have evidence of relapse by ca-125 (2xupper limit of normal) or radiographically within 6 months of most recent platinum-containing chemotherapy. at least one of the lines of chemotherapy must have included a taxane. * must have been treated with debulking surgery and at least one line platinum-based chemotherapy; * subjects may have received up to four additional lines of chemotherapy after they developed platinum-resistance. * subjects must be candidate for repeat paclitaxel treatment exclusion criteria: * clinical contraindications to use of paclitaxel, which include: 1. persistent grade 2 or greater peripheral neuropathy 2. prior hypersensitivity reaction that persisted despite rechallenge with or without desensitization or resulted in bronchospasm or hemodynamic instability or was at least grade 2 and resulted in medication discontinuation * current diagnosis of epithelial ovarian tumor of low malignant potential (borderline carcinomas). note: eoc with prior diagnosis of a low malignant potential tumor that has been surgically resected is acceptable provided the subject did * prior radiation therapy is excluded with the exception that it is allowable only if measurable disease for ovarian cancer is completely outside the radiation portal * known allergic reaction to a prior monoclonal antibody therapy or have any documented human anti-human antibody (haha). * previous treatment with morab-003 (farletuzumab).

Keywords: ovarian cancer relapsed ovarian cancer refractory ovarian cancer
carbamazepine treatment of cocaine dependence - 1

Conditions: Cocaine-Related Disorders; Substance-Related Disorders

Summary: the purpose of this study is to compare the efficacy of carbamazepine in treatment of cocaine-dependence in patients with affective disorders.


Eligibility criteria:
please contact site for information.

Keywords: cocaine substance abuse
the biological specificity of acupoints between major depressive disorder patients and healthy controls

Conditions: Major Depressive Disorder

Summary: evidence-based medicine suggests that acupuncture can improve major depressive disorder (mdd). however, the prevalent reliance on experiential acupoint selection lacks scientific underpinning. the investigators conducted a comparative study involving mdd patients and healthy subjects, employing modern techniques to discern biological specificity in mdd-related acupoints. additionally, the investigators investigated potential correlations between acupoint biological specificity and mdd severity.

a final total of 134 eligible subjects were included. among them, 50 healthy subjects were assigned to the healthy control (hc) group and 84 mdd participants were assigned to the mdd group.

Eligibility criteria:
inclusion criteria: inclusion criteria for the healthy control participants: * provided a recent depression screening report, and be free of any cardiovascular, respiratory, digestive, urinary, hematological, endocrine, or neurological disease; * 18 ≤ age ≤60 years, male or female; * had clear consciousness and could communicate with others normally; - understand the full study protocol and have high adherence; * signed the written informed consent. inclusion criteria for the mdd participants: * consistent with the diagnosis of mdd in the international classification of diseases 10th edition (icd-10); * 18 ≤ age ≤ 60, male or female; * had clear consciousness and could communicate with others normally; * understand the full study protocol and have high adherence; * signed the written informed consent. exclusion criteria: * the exclusion criteria of the hc participants were as follows: (1) had serious primary diseases of cardiovascular diseases, liver diseases, kidney diseases, urinary diseases, and hematological diseases; (2) pregnant or lactating; (3) had scars, hyperpigmentation, red and swollen of the skin at the test site; (4) were participating in other trials; (5) had a mental illness, alcohol dependence, or a history of drug abuse. exclusion criteria for the mdd participants: (1)-(4) same exclusion criteria as healthy subjects; (5) mdd caused by organic mental disorders, schizophrenia, bipolar disorder, psychoactive substances, and non-addictive substances; (6) had psychiatric disorders other than mdd; (7) with suicidal tendencies. in addition, irt is not be performed on female subjects during their menstrual and ovulatory periods.

Keywords: major depressive disorder acupoint biological specificity
effects of urocortins on forearm arterial blood flow in healthy volunteers

Conditions: Vascular Disease; Heart Disease

Summary: impairment of the heart's pumping capacity (heart failure) remains a major clinical problem with a poor prognosis and the search for novel treatments remains an important area of research. urocortins are proteins that appear to increase blood flow and heart pumping activity. there has been particular interest in the role of urocortins 2 \& 3 (subtypes of urocortins) in heart failure. in this study, we will examine the effects and mechanisms of urocortins 2 \& 3 and the corticotrophin releasing hormone receptor type 2 (crh-r2) receptor (through which urocortins act) on forearm blood flow and release of natural blood clot dissolving factors in the forearm circulation of healthy volunteers. in this study, we will look at the role of the lining of the blood vessel (endothelium) in response to urocortin types 2 and 3. we hypothesise that urocortins 2 \& 3 act via the endothelium to cause dilatation of the blood vessels and release of tissue-plasminogen activating factor (blood clot dissolving factor). we also hypothesise that urocortins have a role in maintaining the normal baseline level of blood flow in forearm arteries. in addition to the above, we will also look at the effect of temporarily blocking the effect of urocortins, using a specially designed blocker drug (astressin 2b). utilising the well-established technique of 'forearm venous occlusion plethysmography', we will be able to focus on the local effects of urocortins on arterial blood flow in forearm vessels, without affecting this system in the body as a whole.


Eligibility criteria:
inclusion criteria: * healthy male volunteers between 18 - 65 years (inclusive) exclusion criteria: * lack of informed consent * age \ 65 years * current involvement in a clinical trial * severe or significant co-morbidity including bleeding diathesis, renal or hepatic failure * smoker * history of anaemia * recent infective/inflammatory condition * recent blood donation (prior 3 months) * positive baseline urine test for drugs of abuse (including cannabinoids, benzodiazepines, opiates, cocaine and amphetamines)

Keywords: astressin 2b forearm blood flow vascular plethysmography heart failure